Eisai announces that it will showcase its oncology portfolio and various cancer research achievements both virtually and in-person during the 2024 European Society for Medical Oncology (ESMO) Annual Congress, held from September 13 to 17 in Barcelona, Spain.
"Eisai's Chief Science Officer and Senior Vice President, Dr. Takashi Owa, stated, 'The breakthrough data from the LEAP-012 Phase III trial adds a new chapter to our research in hepatocellular carcinoma, further solidifying Eisai's long-term commitment to improving the quality of life for patients with this fatal disease. We eagerly look forward to sharing these research findings at the ESMO conference, along with other results on lenvatinib as a monotherapy and in combination with pembrolizumab, as well as updates on our R&D pipeline. Such scientific exchanges are crucial as they drive our mission to accelerate progress in oncology and help cancer patients and their families improve their lives.'"
Eisai's Full List of Presentations at the ESMO Congress Now Announced. Regular abstracts will be officially available on the ESMO official website at 12:05 AM CEST on Monday, September 9. Additionally, the latest abstracts selected for proffered paper or mini oral presentations at the ESMO Congress will also go live on the ESMO website at 12:05 AM CEST on their respective presentation days. For poster presentations, specific display times are from 9:00 AM to 5:00 PM CET on each designated poster display day.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120